Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Caspofungin.

G M Keating1, B Jarvis

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|July 24, 2001
PubMed
Summary
This summary is machine-generated.

Caspofungin, a novel glucan synthesis inhibitor, shows efficacy against Aspergillus and Candida species. It offers a treatment option for invasive aspergillosis and candidiasis, with generally good tolerability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reconsideration of the derivation of Most Probable Numbers, their standard deviations, confidence bounds and rarity values.

Journal of applied microbiology·2015
Same author

Application of Illumina next-generation sequencing to characterize the bacterial community of the Upper Mississippi River.

Journal of applied microbiology·2013
Same author

Stachybotrys: An unusual mold associated with water-damaged buildings.

Mycotoxin research·2013
Same author

Reconsideration of the derivation of Most Probable Numbers, their standard deviations, confidence bounds and rarity values.

Journal of applied microbiology·2010
Same author

On the compositing of samples for qualitative microbiological testing.

Letters in applied microbiology·2007
Same author

Estimates of measurement uncertainty from proficiency testing schemes, internal laboratory quality monitoring and during routine enforcement examination of foods.

Journal of applied microbiology·2007
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Mycology
  • Pharmacology

Background:

  • Fungal infections pose significant threats, particularly in immunocompromised individuals.
  • Existing antifungal therapies have limitations in efficacy and tolerability.
  • Caspofungin represents a new class of antifungals targeting fungal cell wall synthesis.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of caspofungin in patients with invasive fungal infections.
  • To assess caspofungin's effectiveness in cases refractory to other antifungal agents.

Main Methods:

  • Noncomparative multicentre studies and randomized double-blind trials were conducted.
  • In vitro and in vivo efficacy was assessed against various fungi and yeasts.
  • Patient response rates, adverse effects, and tolerability compared to other antifungals were documented.

Related Experiment Videos

Main Results:

  • Caspofungin demonstrated efficacy in invasive aspergillosis (40.7% response) and candidiasis.
  • The agent was generally well tolerated, with common adverse effects including fever and nausea.
  • Tolerability was comparable to fluconazole and better than amphotericin B in mucosal candidiasis.

Conclusions:

  • Caspofungin is an effective and generally well-tolerated antifungal agent.
  • It provides a valuable therapeutic option for invasive aspergillosis and candidiasis, especially in patients with limited alternatives.